Abstract

Psoriasis is a prevalent autoimmune disease of the skin that causes significant psychological and physical disability. Tumor necrosis factor (TNF)-blocking agents have proven to be highly efficacious in the management of moderate-to-severe psoriasis. However, a significant percentage of patients do not respond to this treatment. Recently, variation at the PDE3A-SLCO1C1 (phosphodiesterase 3A-SoLute Carrier Organic anion transporter family member 1C1) locus has been robustly associated with anti-TNF response in rheumatoid arthritis. Using a cohort of 130 psoriasis patients treated with anti-TNF therapy, we sought to analyze the association of this locus with treatment response in psoriasis. We found a highly significant association between PDE3A-SLCO1C1 and the clinical response to TNF blockers (P=0.0031). Importantly, the allele that was previously associated with the lack of response to rheumatoid arthritis (G allele, single-nucleotide polymorphism rs3794271) was associated with a higher anti-TNF efficacy in psoriasis. The results of this study are an important step in the characterization of the pharmacogenetic profile associated with anti-TNF response in psoriasis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , . Psoriasis. N Engl J Med 2009; 361: 496–509.

  2. 2.

    , , , , , et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199–204.

  3. 3.

    , , , , , et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42: 991–995.

  4. 4.

    , , , , , et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010; 42: 996–999.

  5. 5.

    , , , , , et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42: 985–990.

  6. 6.

    , , , , , et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 2010; 42: 1005–1009.

  7. 7.

    , , , , , et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010; 42: 1000–1004.

  8. 8.

    , , , , , et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012; 44: 1341–1348.

  9. 9.

    . Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364–371.

  10. 10.

    , , , , , . Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842–1847.

  11. 11.

    , , , . Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenom J 2013; 13: 297–305.

  12. 12.

    , , , , , . Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol 2013; 169: 306–313.

  13. 13.

    , , , , , et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 161: 987–1019.

  14. 14.

    , , . Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866–873.

  15. 15.

    , , , , , et al. Risk variants for psoriasis vulgaris in a large case–control collection and association with clinical subphenotypes. Hum Mol Genet 2012; 21: 4549–4557.

  16. 16.

    , , , , , et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012; 132: 593–600.

  17. 17.

    , , , , , et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genom 2012; 22: 577–589.

  18. 18.

    , , , , , et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 2013; 14: 727–734.

  19. 19.

    , . Severe psoriasis—oral therapy with a new retinoid. Dermatologica 1978; 157: 238–244.

  20. 20.

    , , , , , et al. The role of Fcgamma receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis. A pharmacogenetic study. JAMA Dermatol 2013; 149: 1033–1039.

  21. 21.

    Team RC (2013). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2009.

  22. 22.

    , , , , , et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 2013; 501: 506–511.

  23. 23.

    . Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83: 1583–1590.

  24. 24.

    , , , , , et al. Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. J Invest Dermatol 2003; 120: 285–291.

  25. 25.

    , , , , , et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2013; 121: 898–904.

  26. 26.

    , , , , , et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Acta Dermosifiliogr 2014; 105: 31–44.

  27. 27.

    . Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007–1011.

  28. 28.

    , , , , , et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2013; 28: 907–914.

  29. 29.

    , . The disease activity score and the EULAR response criteria. Rheum Dis Clin N Am 2009; 35: 745–757, vii-viii.

  30. 30.

    , . Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699–711.

  31. 31.

    , , , , . Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513–2518.

  32. 32.

    , , , , , et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209–215.

  33. 33.

    , , , , , et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 2013; 65: 265–271.

  34. 34.

    , , , , , et al. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: a longitudinal study with 6 months of followup. J Rheumatol 2012; 39: 1035–1041.

Download references

Acknowledgements

This work was supported by the Spanish Ministry of Economy and Competitiveness Strategic Project grants (PSE-010000-2006-6, IPT-010000-2010-36).

Author information

Affiliations

  1. Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain

    • A Julià
    • , G Ávila
    • , A Alonso
    • , R Tortosa
    • , M López-Lasanta
    •  & S Marsal
  2. Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

    • C Ferrándiz
  3. Dermatology Department, Hospital Universitario La Princesa, Madrid, Spain

    • E Dauden
  4. Dermatology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

    • E Fonseca
  5. Dermatology Department, Hospital Universitario de Salamanca, Salamanca, Spain

    • E Fernández-López
  6. Dermatology Department, Hospital General Universitario de Valencia, Valencia, Spain

    • J L Sanchez-Carazo
  7. Dermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

    • F Vanaclocha
  8. Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    • L Puig
  9. Dermatology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain

    • D Moreno-Ramírez
  10. Dermatology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain

    • J L Lopez-Estebaranz
  11. Dermatology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain

    • E Herrera
  12. Dermatology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain

    • P de la Cueva

Authors

  1. Search for A Julià in:

  2. Search for C Ferrándiz in:

  3. Search for E Dauden in:

  4. Search for E Fonseca in:

  5. Search for E Fernández-López in:

  6. Search for J L Sanchez-Carazo in:

  7. Search for F Vanaclocha in:

  8. Search for L Puig in:

  9. Search for D Moreno-Ramírez in:

  10. Search for J L Lopez-Estebaranz in:

  11. Search for E Herrera in:

  12. Search for P de la Cueva in:

  13. Search for G Ávila in:

  14. Search for A Alonso in:

  15. Search for R Tortosa in:

  16. Search for M López-Lasanta in:

  17. Search for S Marsal in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to S Marsal.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/tpj.2014.71

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (http://www.nature.com/tpj)

Further reading